US2005232906A1PendingUtilityA1

Adjuvant preparation for the induction of specific immunity

Assignee: UNIV TEXASPriority: May 31, 2000Filed: Mar 29, 2005Published: Oct 20, 2005
Est. expiryMay 31, 2020(expired)· nominal 20-yr term from priority
A61P 35/00C12N 5/0601A61K 2039/55522C12N 2510/00A61K 39/39A61K 2039/55533A61K 38/00A61K 2039/5158A61K 2039/5152A61K 39/0011A61K 2039/5156
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are methods and compositions useful in the recruitment, activation and initiation of proliferation of immune cells. The instant invention relates to the discovery that specific insect cells and insect cell compositions exhibit adjuvant properties. The added benefit of this system is that the insect cells utilized may be transformed with an expression system and thus proteins may be introduced into the composition through direct protein expression by the cells. The claimed compositions and methods are particularly relevant in anti-tumor and cancer therapy. Of specific interest is the ability of the compositions of the invention to elicit a response that controls not only the primary tumor but also any metastatic cells or metastatic tumors which subsequently arise.

Claims

exact text as granted — not AI-modified
1 - 132 . (canceled)  
   
   
       133 . A method of inhibiting cancer growth in a host having a cancer comprising: 
 (a) isolating cancer cells from said host;    (b) rendering said cancer cells inactive;    (c) reintroducing said inactivated cancer cells into said host in a pharmaceutical composition, said pharmaceutical composition further comprising an insect cell composition.    
   
   
       134 . The method of  claim 133 , wherein said insect cell composition further comprises an immunomodulator.  
   
   
       135 . The method of  claim 134 , wherein said immunomodulator is IFNα.  
   
   
       136 . The method of  claim 134 , wherein said immunomodulator is IL-2.  
   
   
       137 . The method of  claim 133 , wherein said cancer is localized.  
   
   
       138 . The method of  claim 133 , wherein said cancer is metastatic.  
   
   
       139 . The method of  claim 140 , wherein said exogenous DNA is a baculovirus expression vector.  
   
   
       140 . The method of  claim 133 , wherein said insect cell composition comprises an exogenous DNA.  
   
   
       141 . The method of  claim 140 , wherein said exogenous construct encodes an immunomodulator.  
   
   
       142 - 194 . (canceled)

Join the waitlist — get patent alerts

Track US2005232906A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.